The 76-Year-Old Venice Artist Who’s Become McQueen’s Latest Muse

Must read

Gilead Sciences on track to snap its six-day winning streak

Shares of Gilead Sciences (NASDAQ:GILD) were on track to end their six-day gaining streak on Thursday, noting their first decline since November 29....

AbbVie shares set for seventh straight session of gains

AbbVie (NYSE:ABBV) shares were on track for their seventh consecutive session of gains on Thursday, as the stock rose nearly 1% to 147.54...

Meta Platforms on track to snap six-day red streak

Meta Platforms' (NASDAQ:META) shares are on track to break a 6-day losing streak after losing about 4.4% over the last 6 trading sessions....

Kenvue gains amid hearing on purported Tylenol linkage to autism in children (update)

Scott Olson/Getty Images News Update 1:35pm: Updates shares, adds court hearing ended. Kenvue Inc. (NYSE:KVUE), the consumer health company...

Venice abstract artist Chuck Arnoldi is famous for incorporating nontraditional materials—like parts of trees—into his paintings. But now, he’s branching out into a new medium: schmattes. The 76-year-old Guggenheim fellow was recently approached by British luxe label Alexander McQueen for collaboration on its spring/summer 2023 line.

“They’d seen a painting of mine and wanted to use it to create dresses for women and suits and T-shirts for men,” Arnoldi says. “I had no idea who or what Alexander McQueen was. Didn’t have a clue.”

But Arnoldi’s wife, novelist Katie Arnoldi, explained who the late designer was and how his company is still producing high-end fashion, and then Arnoldi received a packet of sketches from McQueen’s design team.

“I said to Katie, ‘This stuff looks pretty good.’ I told them, sure, they can use it,” he says. “They offered me 50 grand, and I said, ‘OK.’ I don’t care about the money. My lawyer told me I could have asked for four times as much!”

Stay on top of the latest in L.A. news, food, and culture. Sign up for our newsletters today.

More articles

Latest article

Gilead Sciences on track to snap its six-day winning streak

Shares of Gilead Sciences (NASDAQ:GILD) were on track to end their six-day gaining streak on Thursday, noting their first decline since November 29....

AbbVie shares set for seventh straight session of gains

AbbVie (NYSE:ABBV) shares were on track for their seventh consecutive session of gains on Thursday, as the stock rose nearly 1% to 147.54...

Meta Platforms on track to snap six-day red streak

Meta Platforms' (NASDAQ:META) shares are on track to break a 6-day losing streak after losing about 4.4% over the last 6 trading sessions....

Kenvue gains amid hearing on purported Tylenol linkage to autism in children (update)

Scott Olson/Getty Images News Update 1:35pm: Updates shares, adds court hearing ended. Kenvue Inc. (NYSE:KVUE), the consumer health company...

FedEx shares on track to record its seventh straight session of gains

Sundry Photography/iStock Editorial via Getty Images Global delivery firm FedEx (NYSE:FDX) shares are on track to record its seventh...